Figure 1
Treatment with mepazine reduces experimental autoimmune encephalomyelitis (EAE) severity. (A) Disease progression of mice treated with 8 mg/kg mepazine (n = 14) or vehicle (n = 16) starting at day 7 post-immunization. (B) Percentage body weight of mice treated with 8 mg/kg mepazine (n = 14) or vehicle (n = 16) starting at day 7 post-immunization. (C) Disease progression of naïve mice receiving splenocytes from MOG35-55- immunized, vehicle-treated (n = 5) or mepazine-treated (n = 5) mice. (D) Percentage body weight of naïve mice receiving splenocytes from MOG35-55-immunized, vehicle-treated (n = 5) or mepazine-treated (n = 5) mice. Data are obtained from two independent experiments and depicted as mean ± SEM *P <0.05.